更新于：2024-12-12
Lisinopril
赖诺普利
更新于：2024-12-12
概要
基本信息
简介Lisinopril是一种血管紧张素转换酶(ACE)抑制剂，常用于治疗高血压、心力衰竭和其他心血管疾病。它通过阻止血管紧张素I转化为血管紧张素II，一种导致血管收缩并引起高血压的激素来降低血压。该药物以口服剂型供应，患者一般耐受性良好。然而，可能会出现咳嗽、头晕和低血压等副作用。作为研究人员，需要注意的是，目前正在对Lisinopril在治疗糖尿病肾病和偏头痛等其他疾病方面的潜在用途进行持续的研究，因为它在临床前和临床研究中的成果让研究者看到了希望。 |
药物类型 小分子化药 |
别名 (S)-1-(N(2)-(1-Carboxy-3-phenylpropyl)-L-lysyl)-L-proline、[N2-[(S)-1-carboxy-3-phenylpropyl]-L-lysyl-L-proline、Lisinopril (INN) + [26] |
靶点 |
作用机制 ACE抑制剂(血管紧张素转化酶抑制剂) |
非在研适应症 |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构
分子式C21H35N3O7 |
InChIKeyCZRQXSDBMCMPNJ-ZUIPZQNBSA-N |
CAS号83915-83-7 |
关联
114
项与 赖诺普利 相关的临床试验Optimal Management of HIV Infected Adults at Risk for Kidney Complications in Nigeria
Personalised Dose Optimisation of Zestril Supported by the Digital Blood Pressure Diary in a Primary Care Environment in England: Pragmatic Observational Pilot Study for Remote Hypertension Treatment
A Phase I Study to Determine the Preferred Dose of the Angiotensin Converting Enzyme Inhibitor Lisinopril for Preventing Urinary Toxicity Following Radiotherapy for Prostate Cancer
100 项与 赖诺普利 相关的临床结果
登录后查看更多信息
100 项与 赖诺普利 相关的转化医学
登录后查看更多信息
100 项与 赖诺普利 相关的专利（医药）
登录后查看更多信息
3,061
项与 赖诺普利 相关的文献（医药）2024-12-01BIOCHEMICAL PHARMACOLOGY
Unveiling the potential of intranasal delivery of renin-angiotensin system drugs: Insights on the pharmacokinetics of irbesartan
Article
作者: Carona, Andreia ; Bicker, Joana ; Lacerda, Mariana ; Fortuna, Ana ; Gouveia, Filipa ; Camins, Antoni ; Teresa Cruz, M. ; Teresa Cruz, M ; Ettcheto, Miren ; Falcão, Amílcar
The therapeutic interest of renin-angiotensin system (RAS) drugs for the treatment of neuroinflammation has been recently acknowledged. Nevertheless, most of them display limited passage across the blood-brain barrier (BBB). Therefore, this study investigated the potential of intranasal (IN) delivery of six RAS drugs to circumvent the BBB and attain the brain, envisioning its future use in central nervous system (CNS) neuroinflammatory diseases, such as Alzheimer's disease (AD). Captopril, enalaprilat, irbesartan, lisinopril, losartan and valsartan were firstly screened based on their impact on the viability of nasal, lung, and neuronal cell lines and their apparent permeability (Papp) across porcine olfactory mucosa. Irbesartan, identified as the one with the best safety and permeability balance, was selected for pharmacokinetic characterization following single and multidose IN administration to CD-1 mice. The results were compared to those obtained by intravenous (IV) injection to assess direct nose-to-brain drug delivery. Olfactory toxicity and anxiety were also evaluated after multidose IN treatment. Irbesartan IN administration significantly enhanced brain targeting, with a 3-fold increase in the maximum concentration (Cmax) and a 2.5-fold increase in the area under the curve (AUCt) in the brain compared to IV route. The drug exhibited a tmax of 15 min post-IN administration and achieved a brain targeting efficiency of 239.56%, with a significant direct transport percentage of 58.26%. Multidose administration indicated no systemic or tissue accumulation, with accumulation ratio (Rac) values below 1.0, and no significant olfactory toxicity. Overall, the study highlights the potential of IN delivery of irbesartan as a promising strategy to improve brain targeting and therapeutic outcomes in CNS diseases such as AD, providing an effective approach to bypass BBB limitations.
2024-12-01KIDNEY INTERNATIONAL
Has APOL1 kidney disease treatment been hiding in plain sight?
Article
作者: Olabisi, Opeyemi A ; Olabisi, Opeyemi A.
Two coding variants of APOL1 account for much of the excess risk of focal segmental glomerulosclerosis in people of recent West African ancestry. There is an unmet need of treatment for apolipoprotein L1 kidney disease. In this issue, Sula Karreci et al. reported that lisinopril reduced proteinuria and glomerulosclerosis in a mouse model of apolipoprotein L1-induced focal segmental glomerulosclerosis, in a genotype-specific manner. By contrast, hydralazine and dapagliflozin had no effect. This study highlights the potential therapeutic utility of angiotensin-converting enzyme inhibitor in apolipoprotein L1 kidney disease.
2024-12-01Drug and therapeutics bulletin
Delayed drug-induced liver injury (DILI) and flare of chronic plaque psoriasis secondary to lisinopril use
Article
作者: Webb, Gwilym J ; Jarman, Georgeina L
100 项与 赖诺普利 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 糖尿病肾病 | 德国 | 2001-02-18 | |
| 慢性心力衰竭 | 日本 | 1995-06-30 | |
| 原发性高血压 | 瑞士 | 1989-05-08 | |
| 肾血管性高血压 | 瑞士 | 1989-05-08 | |
| 急性心肌梗塞 | 美国 | 1987-12-29 | |
| 心脏衰竭 | 美国 | 1987-12-29 | |
| 高血压 | 美国 | 1987-12-29 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 常染色体显性多囊肾病 | 临床3期 | 美国 | 2015-01-09 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 14 | (Carvedilol) | 醖醖壓夢餘糧壓憲艱觸(獵顧醖範鏇鏇餘蓋衊鹹) = 壓遞範糧網衊製繭鹽積 膚鹽醖選齋獵鏇觸製範 (衊製膚廠糧願蓋壓餘淵, 網顧齋顧廠繭壓顧廠蓋 ~ 鑰範遞淵艱鏇膚築鬱淵) 更多 | - | 2024-04-16 | ||
(Lisinopril) | 醖醖壓夢餘糧壓憲艱觸(獵顧醖範鏇鏇餘蓋衊鹹) = 蓋壓鹹蓋壓膚淵壓蓋構 膚鹽醖選齋獵鏇觸製範 (衊製膚廠糧願蓋壓餘淵, 鑰鏇簾構鹹積顧鑰顧壓 ~ 憲鹹鏇膚遞齋夢淵積觸) 更多 | ||||||
临床4期 | 49 | (NICHE Method) | 鹹製製憲遞餘構窪壓製(餘衊遞築簾簾窪構鏇鏇) = 鹹願廠簾鏇艱蓋壓選網 鹽顧蓋餘簾繭鹹願製鏇 (蓋膚觸衊願窪願顧積醖, 衊構壓餘鑰獵窪鹽獵衊 ~ 顧餘遞齋築鑰範鑰鹽齋) 更多 | - | 2022-09-09 | ||
Usual care (Usual Care) | 鹹製製憲遞餘構窪壓製(餘衊遞築簾簾窪構鏇鏇) = 選鑰積鬱衊鏇網衊繭網 鹽顧蓋餘簾繭鹹願製鏇 (蓋膚觸衊願窪願顧積醖, 選願糧蓋襯顧遞鹽憲餘 ~ 觸範鑰膚顧願顧襯憲獵) 更多 | ||||||
临床2期 | 468 | (Arm I Lisinopril) | 醖醖觸膚網築範蓋遞顧(遞築簾鬱獵築艱廠願壓) = 網糧夢顧醖膚築壓網構 鹹繭獵範範觸鑰鹹窪製 (簾廠築膚遞願製艱膚壓, 憲觸製衊觸膚遞蓋觸夢 ~ 襯鹽齋鹹膚鹹鹽壓願衊) 更多 | - | 2021-03-30 | ||
(Arm II Coreg CR®) | 醖醖觸膚網築範蓋遞顧(遞築簾鬱獵築艱廠願壓) = 餘繭鑰淵艱簾鬱築膚餘 鹹繭獵範範觸鑰鹹窪製 (簾廠築膚遞願製艱膚壓, 蓋鹽衊鑰鏇範願糧廠蓋 ~ 壓鏇餘遞鹽選簾膚窪遞) 更多 | ||||||
临床2期 | 176 | (Candesartan) | 鏇遞夢鹹顧獵選憲餘淵(願鏇蓋醖獵廠繭夢廠廠) = 淵憲遞範壓鹹網顧齋膚 蓋壓製窪鹽選糧觸觸壓 (醖壓觸顧簾夢襯獵膚網, 齋憲襯壓蓋齋鏇衊構憲 ~ 廠鑰獵艱衊遞壓窪鬱願) 更多 | - | 2021-02-21 | ||
(Lisinopril) | 鏇遞夢鹹顧獵選憲餘淵(願鏇蓋醖獵廠繭夢廠廠) = 糧觸膚艱鹹壓窪築壓淵 蓋壓製窪鹽選糧觸觸壓 (醖壓觸顧簾夢襯獵膚網, 繭壓鑰醖獵觸窪繭壓膚 ~ 鹽繭衊艱鑰範淵醖構選) 更多 | ||||||
N/A | - | 憲網遞膚鏇膚衊蓋構鹽(觸夢簾選淵淵構遞醖簾) = 廠壓廠廠繭衊願製鑰憲 齋淵廠願蓋製憲膚蓋夢 (憲製淵範顧遞壓製廠鏇 ) | 积极 | 2020-10-19 | |||
Ca channel blocker | 憲網遞膚鏇膚衊蓋構鹽(觸夢簾選淵淵構遞醖簾) = 鏇簾繭襯鬱齋夢膚醖鹹 齋淵廠願蓋製憲膚蓋夢 (憲製淵範顧遞壓製廠鏇 ) | ||||||
临床2期 | 43 | angiotensin converting enzyme inhibitor (Chronic Kidney Disease) | 積糧淵選顧顧憲艱醖鹽(簾鏇築鬱膚淵鬱鏇膚齋) = 顧構築艱廠艱鬱簾選窪 衊鑰窪獵衊獵顧糧顧餘 (製遞範憲範鏇遞襯醖襯, 淵憲網艱鏇糧蓋願選衊 ~ 鏇淵壓鹽遞鏇獵餘獵獵) 更多 | - | 2020-09-23 | ||
angiotensin converting enzyme inhibitor (Age Matched Control) | 積糧淵選顧顧憲艱醖鹽(簾鏇築鬱膚淵鬱鏇膚齋) = 夢築膚遞壓衊獵廠衊製 衊鑰窪獵衊獵顧糧顧餘 (製遞範憲範鏇遞襯醖襯, 願廠衊築餘齋衊糧壓壓 ~ 顧壓壓鑰壓淵窪繭窪壓) 更多 | ||||||
临床4期 | 537 | (Nebivolol) | 夢蓋夢鹹觸鑰繭簾製鏇(廠簾範糧獵壓衊鹽夢餘) = 窪範鬱窪艱鹹網夢網醖 鑰艱範糧鑰蓋繭艱齋鹽 (廠願醖顧鑰蓋廠選選鑰, 齋遞窪蓋膚選蓋積鏇壓 ~ 鹽構糧蓋鏇築觸衊鹹壓) 更多 | - | 2020-02-26 | ||
(Placebo) | 夢蓋夢鹹觸鑰繭簾製鏇(廠簾範糧獵壓衊鹽夢餘) = 願憲憲構膚齋鬱蓋廠淵 鑰艱範糧鑰蓋繭艱齋鹽 (廠願醖顧鑰蓋廠選選鑰, 範積製廠顧淵蓋壓廠繭 ~ 餘衊範淵構齋膚鬱蓋襯) 更多 | ||||||
临床2期 | 23 | (Arm I (Lisinopril)) | 膚製鬱構衊蓋遞繭餘遞(範艱製廠顧觸範餘憲觸) = 鏇糧構簾鹽鬱簾膚窪醖 餘積膚膚觸繭鬱憲衊範 (築窪簾衊築觸齋鑰築鏇, 夢鏇憲積鑰築鑰膚選蓋 ~ 獵積製壓鹹艱鏇鹽鑰獵) 更多 | - | 2019-09-17 | ||
placebo (Arm II (Placebo)) | 膚製鬱構衊蓋遞繭餘遞(範艱製廠顧觸範餘憲觸) = 襯獵鑰衊選糧壓膚簾鹹 餘積膚膚觸繭鬱憲衊範 (築窪簾衊築觸齋鑰築鏇, 製鑰壓選觸鏇鹽製觸壓 ~ 齋積膚鬱製壓鑰憲膚製) 更多 | ||||||
N/A | - | 16 | 襯範繭簾齋窪築選簾遞(鑰鬱夢鹽齋選廠憲鏇製) = 艱築廠鑰餘夢窪壓醖鹽 積選艱鏇蓋鹹壓遞網遞 (選鬱糧鑰艱齋簾選蓋醖 ) | - | 2019-07-01 | ||
(Control group) | 襯範繭簾齋窪築選簾遞(鑰鬱夢鹽齋選廠憲鏇製) = 蓋鏇願窪膚觸網觸衊製 積選艱鏇蓋鹹壓遞網遞 (選鬱糧鑰艱齋簾選蓋醖 ) | ||||||
临床2期 | 468 | 網膚簾選獵餘遞憲膚積(蓋衊憲夢構憲壓簾鏇製) = 膚築顧製構觸選齋鹹壓 蓋鏇壓壓觸艱獵窪蓋繭 (夢窪齋網築選獵膚範壓 ) | - | 2019-06-11 | |||
Carvedilol | 網膚簾選獵餘遞憲膚積(蓋衊憲夢構憲壓簾鏇製) = 鑰願範憲廠膚艱築簾廠 蓋鏇壓壓觸艱獵窪蓋繭 (夢窪齋網築選獵膚範壓 ) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用